Corporate Profile
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 trials that is being developed for the treatment of Demodex blepharitis.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Jan 07, 2021
Jan 05, 2021
Dec 23, 2020
Events
Jan 14, 2021 at 2:30 PM EST
Nov 17, 2020 at 10:35 AM GMT
SEC Filings
| Filing date | Description | Form |
|---|---|---|
Initial filing by director officer or owner of more than ten percent. |
3 | |
Statement of changes in beneficial ownership of securities |
4 | |
Statement of changes in beneficial ownership of securities |
4 |